The Pacific Ovarian Cancer Research Consortium (POCRC) is a consortium of five non-profit organizations led by the Fred Hutchinson Cancer Research Center (FHCRC), including the University of Washington (UW), Swedish Medical Center (SMC), Pacific Northwest Research Institute (PNRI), and Cedars Sinai Medical Center (CSMC). POCRC consists of a group of dedicated and enthusiastic scientists from a variety of disciplines who have come together to address the issues that we view as most critical in controlling ovarian cancer. We have identified five areas where opportunities exist for us to make a difference. The first is the identification and elucidation of the function of the genes that mediate chemo-resistance (Project 1). The second is the development of methods to create nucleic acid vaccines to be used eventually in ovarian cancer prevention (Project 2). The third is development of tools to estimate ovarian risk to support the screening and prevention trials that will be required to demonstrate the efficacy of interventions to reduce incidence and mortality from ovarian cancer (Project 3). The fourth is the development of statistical methods for selecting ovarian cancer markers to be included in a screening panel, and for tailoring the use of the panel to the individual woman to improve the efficacy and cost-effectiveness of screening (Project 4). The fifth is performance of a definitive study to demonstrate the efficacy or lack thereof of a facilitated group counseling intervention designed to improve advanced ovarian cancer patients' quality of life (Project 5). The overall challenge of the program is to maintain a high level of interaction among scientists and rapidly communicate novel discoveries throughout the group. A Leadership Core will act as the foundation for scientific interaction, direction, mentoring, and program development. A Clinical Core will provide coordinate and comprehensive procedures for working with physicians to identify eligible women for enrollment in various research studies and activities in the SPORE and interact with the physicians to identify eligible women for enrollment in various research studies and activities in the SPORE and interact with the physicians and health care providers in Washington State to translate the research findings back to the community. A Specimen Core will collect, manage, and analyze tissue and blood products in support of the SPORE research projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA083636-03
Application #
6377537
Study Section
Special Emphasis Panel (ZCA1-GRB-4 (O1))
Program Officer
Arnold, Julia T
Project Start
1999-09-30
Project End
2004-09-29
Budget Start
2001-09-30
Budget End
2002-09-29
Support Year
3
Fiscal Year
2001
Total Cost
$2,444,833
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Hooda, Jagmohan; Novak, Marian; Salomon, Matthew P et al. (2018) Early loss of Histone H2B monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of ovarian cancer. Cancer Res :
Kondrashova, Olga; Topp, Monique; Nesic, Ksenija et al. (2018) Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun 9:3970
Liao, John B; Swensen, Ron E; Ovenell, Kelsie J et al. (2017) Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. Gynecol Oncol 144:480-485
Vragniau, Charles; Hübner, Jens-Martin; Beidler, Peter et al. (2017) Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy. J Virol 91:
Kondrashova, Olga; Nguyen, Minh; Shield-Artin, Kristy et al. (2017) Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov 7:984-998
Au-Yeung, George; Lang, Franziska; Azar, Walid J et al. (2017) Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. Clin Cancer Res 23:1862-1874
Liu, Joyce F; Palakurthi, Sangeetha; Zeng, Qing et al. (2017) Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clin Cancer Res 23:1263-1273
Zheng, Grace X Y; Terry, Jessica M; Belgrader, Phillip et al. (2017) Massively parallel digital transcriptional profiling of single cells. Nat Commun 8:14049
Kroeger Jr, Paul T; Drapkin, Ronny (2017) Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol 29:26-34
Yu-Rice, Yi; Edassery, Seby L; Urban, Nicole et al. (2017) Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer. Reproduction 153:277-284

Showing the most recent 10 out of 187 publications